1. Circulating TP53 Mutations Are Predictive and Prognostic Biomarkers in Pancreatic Cancer Patients Treated with FOLFIRINOX Chemotherapy. (2021) Authors: van der Sijde, F.; Besselink, M.; de Groot, J.W.; Haberkorn, B.; Homs, M.; Luelmo, S.; Mekenkamp, L.; Mustafa, D.; Wilmink, J.; van Eijck, C.; Vietsch, E. Journal: HPB Issue: Volume 23(2021)Supplement 3 Page Start: S681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Diagnostic value of ultra-deep targeted next-generation sequencing in patients with suspect pancreatic and periampullary lesions. (2019) Authors: Sibinga Mulder, B.; Mieog, S.; Farina Sarasqueta, A.; Handgraaf, H.; Vasen, H.; Swijnenburg, R.; Luelmo, S.; Feshtali, S.; Inderson, A.; Vahrmeijer, A.; Bonsing, B.; van Wezel, T.; Morreau, H. Journal: HPB Issue: Volume 21(2019)Supplement 3 Page Start: S688 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Poor surgical outcomes in frail older patients with pancreatic cancer when using VMS as frailty score. (December 2021) Authors: Dekker, R.; Souwer, D.; Berzina, A.; Luelmo, S.; Mieog, S.; Lucassen, C.; Michiels, N.; Portielje, J.; van den Bos, F. Journal: Journal of geriatric oncology Issue: Volume 12(2021)Supplement 1 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗